In a recent assessment of GE HealthCare Techs (GEHC), UBS analyst Graham Doyle has downgraded the stock's rating from 'Neutral' to 'Sell' as of January 15, 2026. Despite the downgrade, the price target has been raised from $73.00 to $77.00, indicating a 5.48% increase. This adjustment reflects a reassessment of the stock's future performance in the market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.